Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC (uHCC) and of Its Treatment with Sorafenib (GIDEON): Differences in AE reporting across physician ...
“To our knowledge, there are no studies evaluating the prognostic importance of CEA and Ca 19-9 in patients with DA [duodenal adenocarcinoma].” Duodenal adenocarcinoma (DA) is a rare malignancy ...
Some patients have a mutation that causes them to not produce CA19-9, a tumor marker often used to help determine prognosis.
A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with ...
A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 ...
Bottom Line: A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite ...
Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. In a new study, researchers Scott Strum, Mark Vincent, Meghan Gipson, Eric McArthur, and Daniel ...
Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data Using a training/validation study design, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results